FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2518827451> ?p ?o ?g. }

• W2518827451 endingPage "28" @default.
• W2518827451 startingPage "28" @default.
• W2518827451 abstract "Numerous studies have evaluated the prognostic value of minimal residual disease (MRD) in patients with multiple myeloma (MM). Most studies were small and varied in terms of patient population, treatment, and MRD assessment methods.To evaluate the utility of MRD detection in patients with newly diagnosed MM.A Medline search was conducted for articles published in English between January 1990 and January 2016.Eligible studies reported MRD status and progression-free survival (PFS) or overall survival (OS) in 20 or more patients following treatment. Among 405 articles identified, 21 met the initial eligibility criteria and were included in the analysis.Information on patient characteristics, treatment, MRD assessment, and outcomes were extracted using a standard form.The impact of MRD status on PFS and OS was assessed by pooling data from relevant trials. Data were adjusted to allow for different proportions of patients with MRD in different studies, and analyzed using the Peto method. Forest plots were created based on Cox model analysis. Other prespecified research questions were addressed qualitatively.Fourteen studies (n = 1273) provided data on the impact of MRD on PFS, and 12 studies (n = 1100) on OS. Results were reported specifically in patients who had achieved conventional complete response (CR) in 5 studies for PFS (n = 574) and 6 studies for OS (n = 616). An MRD-negative status was associated with significantly better PFS overall (hazard ratio [HR], 0.41; 95% CI, 0.36-0.48; P < .001) and in studies specifically looking at CR patients (HR, 0.44; 95% CI, 0.34-0.56; P < .001). Overall survival was also favorable in MRD-negative patients overall (HR, 0.57; 95% CI, 0.46-0.71; P < .001) and in CR patients (HR, 0.47; 95% CI, 0.33-0.67; P < .001). Tests of heterogeneity found no significant differences among the studies for PFS and OS.Minimal residual disease-negative status after treatment for newly diagnosed MM is associated with long-term survival. These findings provide quantitative evidence to support the integration of MRD assessment as an end point in clinical trials of MM." @default.
• W2518827451 created "2016-09-23" @default.
• W2518827451 creator A5003294000 @default.
• W2518827451 creator A5017165070 @default.
• W2518827451 creator A5019191894 @default.
• W2518827451 creator A5028443519 @default.
• W2518827451 creator A5028526208 @default.
• W2518827451 creator A5032464400 @default.
• W2518827451 creator A5036572342 @default.
• W2518827451 creator A5039072697 @default.
• W2518827451 creator A5041668980 @default.
• W2518827451 creator A5045740077 @default.
• W2518827451 creator A5063301766 @default.
• W2518827451 date "2017-01-01" @default.
• W2518827451 modified "2023-10-01" @default.
• W2518827451 title "Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma" @default.
• W2518827451 cites W1526644128 @default.
• W2518827451 cites W1556316630 @default.
• W2518827451 cites W1977691688 @default.
• W2518827451 cites W1977815088 @default.
• W2518827451 cites W1981447363 @default.
• W2518827451 cites W1990372450 @default.
• W2518827451 cites W1990708897 @default.
• W2518827451 cites W1990835696 @default.
• W2518827451 cites W1998925731 @default.
• W2518827451 cites W2003734726 @default.
• W2518827451 cites W2004351861 @default.
• W2518827451 cites W2016998727 @default.
• W2518827451 cites W2017325646 @default.
• W2518827451 cites W2020214644 @default.
• W2518827451 cites W2022227828 @default.
• W2518827451 cites W2025013606 @default.
• W2518827451 cites W2028150271 @default.
• W2518827451 cites W2028286166 @default.
• W2518827451 cites W2039217067 @default.
• W2518827451 cites W2039847348 @default.
• W2518827451 cites W2052220992 @default.
• W2518827451 cites W2063532420 @default.
• W2518827451 cites W2071780943 @default.
• W2518827451 cites W2084797936 @default.
• W2518827451 cites W2086595383 @default.
• W2518827451 cites W2087147671 @default.
• W2518827451 cites W2108485762 @default.
• W2518827451 cites W2132155854 @default.
• W2518827451 cites W2134001103 @default.
• W2518827451 cites W2139260559 @default.
• W2518827451 cites W2144588669 @default.
• W2518827451 cites W2148758597 @default.
• W2518827451 cites W2153337628 @default.
• W2518827451 cites W2161147823 @default.
• W2518827451 cites W2161940278 @default.
• W2518827451 cites W2163941973 @default.
• W2518827451 cites W2209833625 @default.
• W2518827451 cites W2276757615 @default.
• W2518827451 cites W4246655462 @default.
• W2518827451 doi "https://doi.org/10.1001/jamaoncol.2016.3160" @default.
• W2518827451 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5943640" @default.
• W2518827451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27632282" @default.
• W2518827451 hasPublicationYear "2017" @default.
• W2518827451 type Work @default.
• W2518827451 sameAs 2518827451 @default.
• W2518827451 citedByCount "373" @default.
• W2518827451 countsByYear W25188274512016 @default.
• W2518827451 countsByYear W25188274512017 @default.
• W2518827451 countsByYear W25188274512018 @default.
• W2518827451 countsByYear W25188274512019 @default.
• W2518827451 countsByYear W25188274512020 @default.
• W2518827451 countsByYear W25188274512021 @default.
• W2518827451 countsByYear W25188274512022 @default.
• W2518827451 countsByYear W25188274512023 @default.
• W2518827451 crossrefType "journal-article" @default.
• W2518827451 hasAuthorship W2518827451A5003294000 @default.
• W2518827451 hasAuthorship W2518827451A5017165070 @default.
• W2518827451 hasAuthorship W2518827451A5019191894 @default.
• W2518827451 hasAuthorship W2518827451A5028443519 @default.
• W2518827451 hasAuthorship W2518827451A5028526208 @default.
• W2518827451 hasAuthorship W2518827451A5032464400 @default.
• W2518827451 hasAuthorship W2518827451A5036572342 @default.
• W2518827451 hasAuthorship W2518827451A5039072697 @default.
• W2518827451 hasAuthorship W2518827451A5041668980 @default.
• W2518827451 hasAuthorship W2518827451A5045740077 @default.
• W2518827451 hasAuthorship W2518827451A5063301766 @default.
• W2518827451 hasBestOaLocation W25188274512 @default.
• W2518827451 hasConcept C126322002 @default.
• W2518827451 hasConcept C143998085 @default.
• W2518827451 hasConcept C207103383 @default.
• W2518827451 hasConcept C2776364478 @default.
• W2518827451 hasConcept C2778461978 @default.
• W2518827451 hasConcept C2779823535 @default.
• W2518827451 hasConcept C2780739268 @default.
• W2518827451 hasConcept C2908647359 @default.
• W2518827451 hasConcept C3019894029 @default.
• W2518827451 hasConcept C44249647 @default.
• W2518827451 hasConcept C50382708 @default.
• W2518827451 hasConcept C71924100 @default.
• W2518827451 hasConcept C99454951 @default.
• W2518827451 hasConceptScore W2518827451C126322002 @default.
• W2518827451 hasConceptScore W2518827451C143998085 @default.

• next